Ads
related to: montelukast generic for singulair
Search results
Results From The WOW.Com Content Network
Singulair was covered by US Patent No. 5,565,473 [27] which expired on 3 August 2012. [28] The same day, the FDA approved several generic versions of montelukast. [29] The United States Patent and Trademark Office launched a reexamination of the patent covering Singulair on May 2009. The decision was driven by the discovery of references that ...
By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved someone age 19 or younger.
The Food and Drug Administration presented the preliminary results of a study on the asthma drug Singulair, which is sold generically as montelukast, to a "limited audience" at the American ...
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
An antileukotriene, also known as leukotriene modifier and leukotriene receptor antagonist, is a medication which functions as a leukotriene-related enzyme inhibitor (arachidonate 5-lipoxygenase) or leukotriene receptor antagonist (cysteinyl leukotriene receptors) and consequently opposes the function of these inflammatory mediators; leukotrienes are produced by the immune system and serve to ...
The upside to better patient care is unlimited. Unfortunately, from a business perspective, the upside potential of exclusively being able to marketing life-enhancing drugs is finite. 2012 turned ...